Forest Levothroid Misses NDA Approval Deadline; FDA Requests Withdrawal
Executive Summary
Forest Labs must cease distribution of its levothyroxine product Levothroid after failing to receive approval of its pending NDA, FDA said in a warning letter posted on the agency's website Aug. 19
You may also be interested in...
Levothyroxine Review Standards Should Be Same For ANDAs, Brands – Petition
Levothyroxine generics should be held to the same review standards as their 505(b)(2) counterparts, Unithroid manufacturer Jerome Stevens maintained in a 1citizen petition to FDA
Levothyroxine Review Standards Should Be Same For ANDAs, Brands – Petition
Levothyroxine generics should be held to the same review standards as their 505(b)(2) counterparts, Unithroid manufacturer Jerome Stevens maintained in a 1citizen petition to FDA
FDA Seeks To Cut Abbott Synthroid Distribution To 60% By August 2002
An FDA guidance on levothyroxine products calls for Abbott to reduce Synthroid distribution to 60% of current levels by August 2002, about the time the company anticipates FDA approval for the drug.